0

Close
 
Upcoming Allied Market Research
2023
Targeted Liposomes Drug Delivery Market

Targeted Liposomes Drug Delivery Market

by Product (Liposomal  Doxorubicin, Liposomal Amphotericin B  , Liposomal Paclitaxel, Others), by Technology (Stealth Liposome Technology  , Non-PEGylated Liposome Technology  , DepoFoam Liposome Technology, Others) and by Application (Fungal Diseases, Cancer Therapy, Pain Technology, Viral Vaccines, Photodynamic Therapy  , Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Medical Devices & Supplies
Report Code: A12661
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Targeted Liposomes Drug Delivery Market

Request Now !

Liposome refers to a spherical vesicle consisting of more than one lipid bilayers and its interaction in the aqueous phase. The hydrophobic bilayer is constantly repelled by water molecules resulting in a liposome self-assembly. It finds application as a drug delivery agent for delivery pharmaceutical drugs, mRNA vaccines, and DNA vaccines. Additionally, COVID-19 has provided an impetus to the use of liposomes as drug delivery agents, thus decreasing the socio-economic burden. Liposomes find application against fungal diseases, cancer therapy, pain management, viral vaccines, and photodynamic therapy. They are the carriers that have been explored more than any other carrier, due to their various forms right from unilamellar, multi lamellar and giant lamellar. The whole process of liposome drug delivery provides an effective way out of delivering vaccines and genomes due to their targeting ability and corrected gene inputs. The approach results in less side effects as compared to traditional formulations. However, their high cost of production and physical stability act as barriers against market growth.

COVID-19 Impact Analysis

Increase has been witnessed in the demand for medical supplies to take care of infected population. Respiratory support devices such as atomizers, life support machines, oxygen generators, and monitors are among the majorly used medical devices in primary clinical treatment. Moreover, COVID-19 has led to a huge surge in demand for medical supplies such as personal protective equipment including masks, gloves, and protective eyeglasses. The need for medical supplies has increased significantly among both from healthcare professionals and civil population for precautionary measures, owing to rise in number of COVID-19 cases worldwide. Manufacturers of these products have a chance to capitalize this increased demand for medical supplies to ensure adequate and continuous supply of personal protective equipment in the market. Therefore, COVID 19 is expected to have a significant impact on the global liposomes drug delivery market.

Top Impacting Factors

  • Acceptance of liposomes as nano-carriers is providing pharmaceutical players with enhanced techniques such as nanotechnology to enhance drug release profiles. Companies are expanding their research and development infrastructure to optimize drug delivery capabilities of liposomes.
  • Overall enhancements in the understanding of targeted drug delivery systems by various relevant stakeholders, including pharmaceutical firms and government mechanisms might act as an impetus for the growth of use of liposomes as the drug delivery agents.
  • Increase in the number of cases of patients suffering from malignant and benign tumors as well as macrophages and the subsequent need of drugs for cure may act as growth drivers for the industry.
  • Advantages of liposomes over tradition drug delivery systems such as the ability to carry large drug payloads, biocompatibility, and the self-assembly capability has proved to be a major reason for acceptance of liposome as the drug delivery agent.
  • Owing to high cost of production, use of liposomes as regular drug delivery agents may be a far-fetched idea.
  • Major limitations of liposome such as a short half-life and low solubility hamper the market growth.

Key Market Trends

  • Rise of cancer cases all across North America augments the growth of the global liposome drug delivery market.
  • The insights gained from the whole system of using liposomes as drug delivery agents is being used to design liposomes, which can target tissues and cells without the expression of target recognition molecules in its outer membrane. Additional refinements in the liposome drug delivery system may permit selective delivery of therapeutic compounds to sought-after intracellular target areas.
  • Liposomes that exhibit very high or very low pH values are being constructed in a way such that dissolved aqueous drugs are charged in the solution.
  • Further liposomal studies suggest that they can deliver both hydrophilic and hydrophobic drugs for cancer, antifungal, immunomodulation, and antibacterial diseases.

Key Benefits of the Report

  • This study presents the analytical depiction of the targeted liposomes drug delivery industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the testing growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Targeted Liposomes Drug Delivery Report

  • Which are the leading players active in the Targeted Liposomes Drug Delivery market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the Targeted Liposomes Drug Delivery market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is Targeted Liposomes Drug Delivery?
  • What is the Targeted Liposomes Drug Delivery market prediction in the future?
  • What are the current trends and predicted trends?

 Targeted Liposomes Drug Delivery Market Report Highlights

Aspects Details
By Product
  • Liposomal  Doxorubicin
  • Liposomal Amphotericin B  
  • Liposomal Paclitaxel
  • Others
By Technology
  • Stealth Liposome Technology  
  • Non-PEGylated Liposome Technology  
  • DepoFoam Liposome Technology
  • Others
By Application
  • Fungal Diseases
  • Cancer Therapy
  • Pain Technology
  • Viral Vaccines
  • Photodynamic Therapy  
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Pacira BioSciences, Inc., Takeda Pharmaceutical Company Limited, Ipsen Pharma, Spectrum Pharmaceuticals, Inc., Novartis AG, Luye Pharma Group, Astellas Pharma, Inc., Gilead Sciences, Inc., Johnson and Johnson, Celsion Corporation
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: TARGETED LIPOSOMES DRUG DELIVERY MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Liposomal  Doxorubicin

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Liposomal Amphotericin B  

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Liposomal Paclitaxel

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Others

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: TARGETED LIPOSOMES DRUG DELIVERY MARKET, BY TECHNOLOGY

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Technology

    • 5.2. Stealth Liposome Technology  

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Non-PEGylated Liposome Technology  

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. DepoFoam Liposome Technology

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Others

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: TARGETED LIPOSOMES DRUG DELIVERY MARKET, BY APPLICATION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Application

    • 6.2. Fungal Diseases

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Cancer Therapy

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Pain Technology

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Viral Vaccines

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

    • 6.6. Photodynamic Therapy  

      • 6.6.1. Key Market Trends, Growth Factors and Opportunities

      • 6.6.2. Market Size and Forecast, By Region

      • 6.6.3. Market Share Analysis, By Country

    • 6.7. Others

      • 6.7.1. Key Market Trends, Growth Factors and Opportunities

      • 6.7.2. Market Size and Forecast, By Region

      • 6.7.3. Market Share Analysis, By Country

  • CHAPTER 7: TARGETED LIPOSOMES DRUG DELIVERY MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Product

      • 7.2.3. Market Size and Forecast, By Technology

      • 7.2.4. Market Size and Forecast, By Application

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Targeted Liposomes Drug Delivery Market

        • 7.2.6.1. Market Size and Forecast, By Product
        • 7.2.6.2. Market Size and Forecast, By Technology
        • 7.2.6.3. Market Size and Forecast, By Application

      • 7.2.7. Canada Targeted Liposomes Drug Delivery Market

        • 7.2.7.1. Market Size and Forecast, By Product
        • 7.2.7.2. Market Size and Forecast, By Technology
        • 7.2.7.3. Market Size and Forecast, By Application

      • 7.2.8. Mexico Targeted Liposomes Drug Delivery Market

        • 7.2.8.1. Market Size and Forecast, By Product
        • 7.2.8.2. Market Size and Forecast, By Technology
        • 7.2.8.3. Market Size and Forecast, By Application

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Product

      • 7.3.3. Market Size and Forecast, By Technology

      • 7.3.4. Market Size and Forecast, By Application

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Targeted Liposomes Drug Delivery Market

        • 7.3.6.1. Market Size and Forecast, By Product
        • 7.3.6.2. Market Size and Forecast, By Technology
        • 7.3.6.3. Market Size and Forecast, By Application

      • 7.3.7. Germany Targeted Liposomes Drug Delivery Market

        • 7.3.7.1. Market Size and Forecast, By Product
        • 7.3.7.2. Market Size and Forecast, By Technology
        • 7.3.7.3. Market Size and Forecast, By Application

      • 7.3.8. Italy Targeted Liposomes Drug Delivery Market

        • 7.3.8.1. Market Size and Forecast, By Product
        • 7.3.8.2. Market Size and Forecast, By Technology
        • 7.3.8.3. Market Size and Forecast, By Application

      • 7.3.9. Spain Targeted Liposomes Drug Delivery Market

        • 7.3.9.1. Market Size and Forecast, By Product
        • 7.3.9.2. Market Size and Forecast, By Technology
        • 7.3.9.3. Market Size and Forecast, By Application

      • 7.3.10. UK Targeted Liposomes Drug Delivery Market

        • 7.3.10.1. Market Size and Forecast, By Product
        • 7.3.10.2. Market Size and Forecast, By Technology
        • 7.3.10.3. Market Size and Forecast, By Application

      • 7.3.11. Russia Targeted Liposomes Drug Delivery Market

        • 7.3.11.1. Market Size and Forecast, By Product
        • 7.3.11.2. Market Size and Forecast, By Technology
        • 7.3.11.3. Market Size and Forecast, By Application

      • 7.3.12. Rest Of Europe Targeted Liposomes Drug Delivery Market

        • 7.3.12.1. Market Size and Forecast, By Product
        • 7.3.12.2. Market Size and Forecast, By Technology
        • 7.3.12.3. Market Size and Forecast, By Application

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Product

      • 7.4.3. Market Size and Forecast, By Technology

      • 7.4.4. Market Size and Forecast, By Application

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Targeted Liposomes Drug Delivery Market

        • 7.4.6.1. Market Size and Forecast, By Product
        • 7.4.6.2. Market Size and Forecast, By Technology
        • 7.4.6.3. Market Size and Forecast, By Application

      • 7.4.7. Japan Targeted Liposomes Drug Delivery Market

        • 7.4.7.1. Market Size and Forecast, By Product
        • 7.4.7.2. Market Size and Forecast, By Technology
        • 7.4.7.3. Market Size and Forecast, By Application

      • 7.4.8. India Targeted Liposomes Drug Delivery Market

        • 7.4.8.1. Market Size and Forecast, By Product
        • 7.4.8.2. Market Size and Forecast, By Technology
        • 7.4.8.3. Market Size and Forecast, By Application

      • 7.4.9. South Korea Targeted Liposomes Drug Delivery Market

        • 7.4.9.1. Market Size and Forecast, By Product
        • 7.4.9.2. Market Size and Forecast, By Technology
        • 7.4.9.3. Market Size and Forecast, By Application

      • 7.4.10. Australia Targeted Liposomes Drug Delivery Market

        • 7.4.10.1. Market Size and Forecast, By Product
        • 7.4.10.2. Market Size and Forecast, By Technology
        • 7.4.10.3. Market Size and Forecast, By Application

      • 7.4.11. Thailand Targeted Liposomes Drug Delivery Market

        • 7.4.11.1. Market Size and Forecast, By Product
        • 7.4.11.2. Market Size and Forecast, By Technology
        • 7.4.11.3. Market Size and Forecast, By Application

      • 7.4.12. Malaysia Targeted Liposomes Drug Delivery Market

        • 7.4.12.1. Market Size and Forecast, By Product
        • 7.4.12.2. Market Size and Forecast, By Technology
        • 7.4.12.3. Market Size and Forecast, By Application

      • 7.4.13. Indonesia Targeted Liposomes Drug Delivery Market

        • 7.4.13.1. Market Size and Forecast, By Product
        • 7.4.13.2. Market Size and Forecast, By Technology
        • 7.4.13.3. Market Size and Forecast, By Application

      • 7.4.14. Rest of Asia Pacific Targeted Liposomes Drug Delivery Market

        • 7.4.14.1. Market Size and Forecast, By Product
        • 7.4.14.2. Market Size and Forecast, By Technology
        • 7.4.14.3. Market Size and Forecast, By Application

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Product

      • 7.5.3. Market Size and Forecast, By Technology

      • 7.5.4. Market Size and Forecast, By Application

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Targeted Liposomes Drug Delivery Market

        • 7.5.6.1. Market Size and Forecast, By Product
        • 7.5.6.2. Market Size and Forecast, By Technology
        • 7.5.6.3. Market Size and Forecast, By Application

      • 7.5.7. South Africa Targeted Liposomes Drug Delivery Market

        • 7.5.7.1. Market Size and Forecast, By Product
        • 7.5.7.2. Market Size and Forecast, By Technology
        • 7.5.7.3. Market Size and Forecast, By Application

      • 7.5.8. Saudi Arabia Targeted Liposomes Drug Delivery Market

        • 7.5.8.1. Market Size and Forecast, By Product
        • 7.5.8.2. Market Size and Forecast, By Technology
        • 7.5.8.3. Market Size and Forecast, By Application

      • 7.5.9. UAE Targeted Liposomes Drug Delivery Market

        • 7.5.9.1. Market Size and Forecast, By Product
        • 7.5.9.2. Market Size and Forecast, By Technology
        • 7.5.9.3. Market Size and Forecast, By Application

      • 7.5.10. Argentina Targeted Liposomes Drug Delivery Market

        • 7.5.10.1. Market Size and Forecast, By Product
        • 7.5.10.2. Market Size and Forecast, By Technology
        • 7.5.10.3. Market Size and Forecast, By Application

      • 7.5.11. Rest of LAMEA Targeted Liposomes Drug Delivery Market

        • 7.5.11.1. Market Size and Forecast, By Product
        • 7.5.11.2. Market Size and Forecast, By Technology
        • 7.5.11.3. Market Size and Forecast, By Application

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Spectrum Pharmaceuticals, Inc.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Astellas Pharma, Inc.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Gilead Sciences, Inc.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Celsion Corporation

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Ipsen Pharma

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Pacira BioSciences, Inc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Luye Pharma Group

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Novartis AG

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Johnson And Johnson

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Takeda Pharmaceutical Company Limited

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR LIPOSOMAL  DOXORUBICIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR LIPOSOMAL AMPHOTERICIN B  , BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR LIPOSOMAL PACLITAXEL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR STEALTH LIPOSOME TECHNOLOGY  , BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR NON-PEGYLATED LIPOSOME TECHNOLOGY  , BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR DEPOFOAM LIPOSOME TECHNOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR FUNGAL DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR CANCER THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR PAIN TECHNOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR VIRAL VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR PHOTODYNAMIC THERAPY  , BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA TARGETED LIPOSOMES DRUG DELIVERY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. U.S. TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 24. U.S. TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 25. U.S. TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. CANADA TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 27. CANADA TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 28. CANADA TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE TARGETED LIPOSOMES DRUG DELIVERY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 39. GERMANY TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 40. GERMANY TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 41. GERMANY TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. ITALY TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 43. ITALY TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 44. ITALY TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. UK TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 49. UK TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 50. UK TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. RUSSIA TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 52. RUSSIA TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 53. RUSSIA TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 54. REST OF EUROPE TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 55. REST OF EUROPE TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 56. REST OF EUROPE TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 57. ASIA-PACIFIC TARGETED LIPOSOMES DRUG DELIVERY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 58. ASIA-PACIFIC TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 59. ASIA-PACIFIC TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 60. ASIA-PACIFIC TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. CHINA TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 62. CHINA TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 63. CHINA TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. JAPAN TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 65. JAPAN TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 66. JAPAN TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. INDIA TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 68. INDIA TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 69. INDIA TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH KOREA TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 71. SOUTH KOREA TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 72. SOUTH KOREA TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 73. AUSTRALIA TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 74. AUSTRALIA TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 75. AUSTRALIA TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 76. THAILAND TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 77. THAILAND TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 78. THAILAND TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 79. MALAYSIA TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 80. MALAYSIA TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 81. MALAYSIA TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 82. INDONESIA TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 83. INDONESIA TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 84. INDONESIA TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 85. REST OF ASIA PACIFIC TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 86. REST OF ASIA PACIFIC TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 87. REST OF ASIA PACIFIC TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 88. LAMEA TARGETED LIPOSOMES DRUG DELIVERY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 89. LAMEA TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 90. LAMEA TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 91. LAMEA TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 92. BRAZIL TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 93. BRAZIL TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 94. BRAZIL TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH AFRICA TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 96. SOUTH AFRICA TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 97. SOUTH AFRICA TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 98. SAUDI ARABIA TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 99. SAUDI ARABIA TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 100. SAUDI ARABIA TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 101. UAE TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 102. UAE TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 103. UAE TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 104. ARGENTINA TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 105. ARGENTINA TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 106. ARGENTINA TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 107. REST OF LAMEA TARGETED LIPOSOMES DRUG DELIVERY, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 108. REST OF LAMEA TARGETED LIPOSOMES DRUG DELIVERY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 109. REST OF LAMEA TARGETED LIPOSOMES DRUG DELIVERY, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 110. SPECTRUM PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 111. SPECTRUM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 112. SPECTRUM PHARMACEUTICALS, INC.: OPERATING SEGMENTS
  • TABLE 113. SPECTRUM PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 114. SPECTRUM PHARMACEUTICALS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. ASTELLAS PHARMA, INC.: KEY EXECUTIVES
  • TABLE 116. ASTELLAS PHARMA, INC.: COMPANY SNAPSHOT
  • TABLE 117. ASTELLAS PHARMA, INC.: OPERATING SEGMENTS
  • TABLE 118. ASTELLAS PHARMA, INC.: PRODUCT PORTFOLIO
  • TABLE 119. ASTELLAS PHARMA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. GILEAD SCIENCES, INC.: KEY EXECUTIVES
  • TABLE 121. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 122. GILEAD SCIENCES, INC.: OPERATING SEGMENTS
  • TABLE 123. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 124. GILEAD SCIENCES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 125. CELSION CORPORATION: KEY EXECUTIVES
  • TABLE 126. CELSION CORPORATION: COMPANY SNAPSHOT
  • TABLE 127. CELSION CORPORATION: OPERATING SEGMENTS
  • TABLE 128. CELSION CORPORATION: PRODUCT PORTFOLIO
  • TABLE 129. CELSION CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 130. IPSEN PHARMA: KEY EXECUTIVES
  • TABLE 131. IPSEN PHARMA: COMPANY SNAPSHOT
  • TABLE 132. IPSEN PHARMA: OPERATING SEGMENTS
  • TABLE 133. IPSEN PHARMA: PRODUCT PORTFOLIO
  • TABLE 134. IPSEN PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 135. PACIRA BIOSCIENCES, INC.: KEY EXECUTIVES
  • TABLE 136. PACIRA BIOSCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 137. PACIRA BIOSCIENCES, INC.: OPERATING SEGMENTS
  • TABLE 138. PACIRA BIOSCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 139. PACIRA BIOSCIENCES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 140. LUYE PHARMA GROUP: KEY EXECUTIVES
  • TABLE 141. LUYE PHARMA GROUP: COMPANY SNAPSHOT
  • TABLE 142. LUYE PHARMA GROUP: OPERATING SEGMENTS
  • TABLE 143. LUYE PHARMA GROUP: PRODUCT PORTFOLIO
  • TABLE 144. LUYE PHARMA GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 146. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 147. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 148. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 149. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 151. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 152. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 153. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 154. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 155. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY EXECUTIVES
  • TABLE 156. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
  • TABLE 157. TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS
  • TABLE 158. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
  • TABLE 159. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET SEGMENTATION
  • FIGURE 2. GLOBAL TARGETED LIPOSOMES DRUG DELIVERY MARKET
  • FIGURE 3. SEGMENTATION TARGETED LIPOSOMES DRUG DELIVERY MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN TARGETED LIPOSOMES DRUG DELIVERY MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALTARGETED LIPOSOMES DRUG DELIVERY MARKET
  • FIGURE 11. TARGETED LIPOSOMES DRUG DELIVERY MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR LIPOSOMAL  DOXORUBICIN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR LIPOSOMAL AMPHOTERICIN B  , BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR LIPOSOMAL PACLITAXEL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. TARGETED LIPOSOMES DRUG DELIVERY MARKET SEGMENTATION, BY BY TECHNOLOGY
  • FIGURE 17. TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR STEALTH LIPOSOME TECHNOLOGY  , BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR NON-PEGYLATED LIPOSOME TECHNOLOGY  , BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR DEPOFOAM LIPOSOME TECHNOLOGY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. TARGETED LIPOSOMES DRUG DELIVERY MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 22. TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR FUNGAL DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR CANCER THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR PAIN TECHNOLOGY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR VIRAL VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR PHOTODYNAMIC THERAPY  , BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. TARGETED LIPOSOMES DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 29. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 30. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 31. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 32. COMPETITIVE DASHBOARD
  • FIGURE 33. COMPETITIVE HEATMAP: TARGETED LIPOSOMES DRUG DELIVERY MARKET
  • FIGURE 34. Top player positioning, 2022
  • FIGURE 35. SPECTRUM PHARMACEUTICALS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. SPECTRUM PHARMACEUTICALS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. SPECTRUM PHARMACEUTICALS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. ASTELLAS PHARMA, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. ASTELLAS PHARMA, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. ASTELLAS PHARMA, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. GILEAD SCIENCES, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. GILEAD SCIENCES, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. GILEAD SCIENCES, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. CELSION CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. CELSION CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. CELSION CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. IPSEN PHARMA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. IPSEN PHARMA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. IPSEN PHARMA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. PACIRA BIOSCIENCES, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. PACIRA BIOSCIENCES, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. PACIRA BIOSCIENCES, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. LUYE PHARMA GROUP: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. LUYE PHARMA GROUP: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. LUYE PHARMA GROUP: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 56. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 58. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 59. JOHNSON AND JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 61. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 62. TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. TAKEDA PHARMACEUTICAL COMPANY LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 64. TAKEDA PHARMACEUTICAL COMPANY LIMITED: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Targeted Liposomes Drug Delivery Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers